+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

eCOA/ePRO Market Dynamics and Service Provider Performance (4th Edition)

  • ID: 5232285
  • Report
  • March 2021
  • Region: Global
  • Industry Standard Research (ISR)

FEATURED COMPANIES

  • Almac
  • Clinical Ink
  • ERT
  • IQVIA
  • Medable
  • THREAD

There’s no question that technology is continuously becoming more prevalent in the clinical development space and electronic clinical outcomes assessments (eCOA) and electronic patient reported outcomes (ePRO) systems are no exception. Over the past several years, eCOA/ePRO systems are now considered the norm and are necessary tools to properly capture, review, and even present data collected throughout the course of a clinical trial. The publisher has been tracking the eCOA/ePRO market for over a decade and one thing is for certain - eCOA/ePRO applications are here to stay. As technology in the eCOA/ePRO space continues to change, more sponsors and CROs rely on these systems to ensure high quality data, lower costs, and fewer delays.

eCOA/ePRO providers and sponsor/CRO organizations will gain valuable insight using this research. For eCOA/ePRO providers: Learn how your company performs against competitors. Discover where performance exceeds expectations so you can differentiate your offerings from competitors. For sponsors/CROs: Compare your company’s outsourcing philosophy to that of the broader industry. Evaluate your provider selection process. Explore new providers and understand how they have performed for industry peers.

What you will learn:

Sponsors and CROs:

  • Nearly 200 service provider encounters with 18 eCOA/ePRO systems
  • Bird’s eye view of the eCOA/ePRO market and provider preference for development and late-stage trials, criteria used for provider selection, and service provider performance
  • Allow readers to narrow down which eCOA/ePRO system might best fit their needs, enabling readers to make a more informed decision when selecting eCOA/ePRO services
  • Which eCOA/ePRO systems are being most utilized by your peers

Technology Providers:

  • Benchmark your performance against your competition
  • Anticipate how changes in trial volume and adoption/penetration will affect your future business opportunities
  • Identify operational improvements and product characteristics that impact trial success, especially device integration and user-friendliness
  • Understand your company’s and the competition’s position in the marketplace in terms of familiarity and use, and your company’s performance on 28 attributes across 6 categories relative to user expectations

Major Topics:

  • Part I: Market Dynamics
    • Market Environment
    • Provider Selection Criteria
    • Study Data
  • Part II: Provider Performance
    • Provider Perceptions
    • Provider Performance
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Almac
  • Clinical Ink
  • ERT
  • IQVIA
  • Medable
  • THREAD

Part I: Market Dynamics

1. Market Environment

  • Primary Section Takeaways
  • Systems Usage
  • Preferred Provider Agreements
  • Preference for eCOA/ePRO vs. Paper Diaries
  • Use of Electronic Solutions vs. Paper
  • Preference for Device-based Interface
  • Use of Direct Data Capture Sensors/Wearables for Patient Measurements
  • Source of Clinical Reported Outcomes (Past and Projected)
  • Source of Clinical Outcomes Assessments
  • How to Improve Functionality of eCOA/ePRO Software Systems
  • Impact of eCOA/ePRO Product Attributes on Trial Success

2. Provider Selection Criteria

  • Primary Section Takeaways
  • Most Important Attributes for Provider Selection
  • Influencing Sponsor In-house Provider Selection
  • Influencing CRO Provider Selection
  • Influence of Sponsors on Provider Selection for Outsourced Studies

3. Study Data

  • Most Important Attributes for Provider Selection
  • Impact of eCOA/ePRO Product Attributes on Trial Success
  • Use of Electronic Solutions vs. Paper (Past and Projected)
  • Number of eCOA/ePRO Systems Used (Current and Projected)
  • Preferred Provider Agreements
  • Influencing Provider Selection (In-House Studies)
  • Influencing Provider Selection (CROs)
  • Influence of Sponsors on Provider Selection for Outsourced Studies
  • Contract Directly vs. through CRO for eCOA/ePRO Components
  • Sponsor Contract Directly with CRO vs. through eCOA/ePRO Provider
  • Preference for eCOA/ePRO vs. Paper Diaries
  • Preference for Device-based Interface
  • Knowledge of eCOA/ePRO Component Use in Clinical Trials
  • Percent of Trials Using eCOA/ePRO Component (Past and Projected)
  • Use of Direct Data Capture Sensors/Wearables for Patient Measurements (Past and Projected)
  • Source of Clinical Outcome Assessments (Past and Projected)
  • Source of Clinical Reported Outcomes (Past and Projected)
  • How to Improve Functionality of eCOA/ePRO Software Systems - Themed
  • Verbatim Responses: How to Improve Functionality of eCOA/ePRO Software Systems

4. Demographics

  • Company Type
  • Decision-making Responsibility
  • Type of Office/Practice
  • Most Recent Clinical Trial
  • Involvement in Clinical Trials (Past 12 months)
  • Role of Organization in Clinical Trial
  • Roles and Responsibilities
  • Office Location
  • Therapeutic Areas of Responsibility
  • Technology Familiarity

Part II: Provider Performance

5. Provider Perceptions

  • Primary Section Takeaways
  • Provider Usage and Familiarity
  • Past Use/Experience Level with Providers
  • Provider Preference by Trial Stage
  • Phase I and II Development Stage
  • Phase IIb and III Development Stage
  • Phase IV, Post-marketing Late-stage

6. Provider Performance

  • Primary Section Takeaways
  • A Note on Performance Calculations
  • Performance Across Service Providers
  • Figure 1 - Capabilities
  • Figure 2 - Cost
  • Figure 3 - System Flexibility and Support
  • Figure 4 - System/Device Integration
  • Figure 5 - Usability
  • Figure 6 - Validation and Patient Compliance

7. Company Service Quality Profiles

  • Almac
  • ERT
  • ICON
  • IQVIA
  • Medidata/Dassault Systemes (Rave)
  • Parexel
  • Signant Health (SmartSignals/TrialMax)

8. Attribute Performance

  • Almac
  • ArisGlobal (LifeSphere)
  • Clinical Ink
  • DataTrak (Direct)
  • ERT
  • ICON
  • IQVIA
  • Kayentis
  • Medable
  • MedAvante-Prophase, a WCG Company (Virgil PRO)
  • Medidata/Dassault Systemes (Rave)
  • Parexel
  • Signant Health (SmartSignals/TrialMax)
  • THREAD
  • uMotif
  • Viedoc (ViedocMe)
  • WCG (WIRB-Copernicus Group)
  • YPrime

9. Demographics

  • Company Type
  • Decision-making Responsibility (Sponsors)
  • Involvement in Clinical Trials (Past 12 months)
  • Type of Office/Practice
  • Most Recent Clinical Trial
  • Role of Organization in Clinical Trial
  • Roles and Responsibilities
  • Office Location
  • Therapeutic Areas of Responsibility
  • Technology Familiarity
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Almac
  • ArisGlobal (LifeSphere)
  • Clinical Ink
  • DataTrak (Direct)
  • ERT
  • ICON
  • IQVIA
  • Kayentis
  • Medable
  • MedAvante-Prophase, a WCG Company (Virgil PRO)
  • Medidata/Dassault Systemes (Rave)
  • Parexel
  • Signant Health (SmartSignals/TrialMax)
  • THREAD
  • uMotif
  • Viedoc (ViedocMe)
  • WCG (WIRB-Copernicus Group)
  • YPrime
Note: Product cover images may vary from those shown
Adroll
adroll